Monte Rosa Therapeutics, Inc. (GLUE)
10.30
-0.02
(-0.19%)
USD |
NASDAQ |
Oct 09, 16:00
10.30
0.00 (0.00%)
After-Hours: 20:00
Monte Rosa Therapeutics Gross Profit Margin (Quarterly) : 78.69% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 78.69% |
| March 31, 2026 | 51.81% |
| December 31, 2025 | 24.92% |
| September 30, 2025 | 83.59% |
| June 30, 2025 | 90.84% |
| Date | Value |
|---|---|
| March 31, 2025 | 97.59% |
| December 31, 2024 | 96.60% |
| September 30, 2024 | 77.18% |
| June 30, 2024 | 56.12% |
| March 31, 2024 | -78.29% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| United Therapeutics Corp. | 87.30% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -45.87% |
| Return on Assets | -29.88% |
| Return on Invested Capital | -41.23% |
| Profit Margin (Quarterly) | -483.9% |
| Operating Margin (Quarterly) | -547.8% |
| Return on Net Operating Assets | -296.3% |